본문 바로가기
KERD
논문KCI 등재

급성기 양극성우울증 약물치료 전략

Pharmacological Treatment Strategies for Acute Bipolar Depression

김세주
대한신경정신의학회 (Korean Neuropsychiatric Association)|2018.11|신경정신의학 (JOURNAL OF THE KOREAN NEUROPSYCHIATRIC ASSOCIATION)|제57권 제4호|pp. 287-300|DOI https://doi.org/10.4306/jknpa.2018.57.4.287

2

조회

0

다운로드

2

인용

0

참고문헌

키워드

Treatment guidelineAntidepressants.Atypical antipsychoticsMood stabilizersAcute bipolar depression
주제분류정신과학

초록

Of the different phases of bipolar disorder, bipolar depression is more prevailing and is more difficult to treat. However, there is a deficit in systemic research on the pharmacological treatment of acute bipolar depression. Therefore, consensuses on the pharmacological treatment strategies of acute bipolar depression has yet to be made. Currently, there are only three drugs approved by the Food and Drug Administration for acute bipolar depression : quetiapine, olanzapine-fluoxetine complex, and lurasidone. In clinical practice, other drugs such as mood stabilizers (lamotrigine, lithium, valproate) and/or the other atypical antipsychotics (aripiprazole, risperidone, ziprasidone) are frequently prescribed. There remains controversy on the use of antidepressants in bipolar depression. Here, we summarized the evidence of current pharmacological treatment options and reviewed treatment guidelines of acute bipolar depression from recently published studies.

Abstract

Of the different phases of bipolar disorder, bipolar depression is more prevailing and is more difficult to treat. However, there is a deficit in systemic research on the pharmacological treatment of acute bipolar depression. Therefore, consensuses on the pharmacological treatment strategies of acute bipolar depression has yet to be made. Currently, there are only three drugs approved by the Food and Drug Administration for acute bipolar depression : quetiapine, olanzapine-fluoxetine complex, and lurasidone. In clinical practice, other drugs such as mood stabilizers (lamotrigine, lithium, valproate) and/or the other atypical antipsychotics (aripiprazole, risperidone, ziprasidone) are frequently prescribed. There remains controversy on the use of antidepressants in bipolar depression. Here, we summarized the evidence of current pharmacological treatment options and reviewed treatment guidelines of acute bipolar depression from recently published studies.

참고문헌 (89)

  1. Baldessarini RJ, "Morbidity in 303 first-episode bipolar I disorder patients", Bipolar Disord, 12, pp.264~270 (2010)
  2. Judd LL, "The long-term natural history of the weekly symptomatic status of bipolar I disorder", Arch Gen Psychiatry, 59, pp.530~537 (2002)
  3. Judd LL, "A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder", Arch Gen Psychiatry, 60, pp.261~269 (2003)
  4. Post RM, "A re-evaluation of the role of antidepressants in the treatment of bipolar depression : data from the Stanley Foundation Bipolar Network", Bipolar Disord, 5, pp.396~406 (2003)
  5. Miller S, "The prevalence and burden of bipolar depression", J Affect Disord, 169(Suppl 1), pp.S3~S11 (2014)
  6. Yatham LN, "Canadian Network for Mood and Anxiety Treatments(CANMAT)and International Society for Bipolar Disorders(ISBD)2018 guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
  7. Mitchell PB, "Diagnostic guidelines for bipolar depression : a probabilistic approach", Bipolar Disord, 10, pp.144~152 (2008)
  8. Schaffer A, "A population-based analysis of distinguishers of bipolar disorder from major depressive disorder", J Affect Disord, 125, pp.103~110 (2010)
  9. Narei Hong, "Improving the Screening Instrument of Bipolar Spectrum Disorders: Weighted Korean Version of the Mood Disorder Questionnaire", Clinical Psychopharmacology and Neuroscience, 16(3), pp.333~338 (2018), 대한정신약물학회[DOI]
  10. Bobo WV, "The diagnosis and management of bipolar I and II disorders : clinical practice update", Mayo Clin Proc, 92, pp.1532~1551 (2017)
  11. Baldessarini RJ, "Pharmacological treatment of adult bipolar disorder", Mol Psychiatry (2018)
  12. Prieto E, "Neurobiological bases of quetiapine antidepresant effect in the bipolar disorder", Actas Esp Psiquiatr, 38, pp.22~32 (2010)
  13. Calabrese JR, "A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression", Am J Psychiatry, 162, pp.1351~1360 (2005)
  14. Thase ME, "Efficacy of quetiapine monotherapy in bipolar I and II depression:a double-blind, placebo-controlled study (the BOLDER II study)", J Clin Psychopharmacol, 26, pp.600~609 (2006)
  15. McElroy SL, "A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II)", J Clin Psychiatry, 71, pp.163~174 (2010)
  16. Young AH, "A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I)", J Clin Psychiatry, 71, pp.150~162 (2010)
  17. Murasaki M, "Multi-center, randomized, double-blind, placebo-controlled study of quetiapine extended-release formulation in Japanese patients with bipolar depression", Psychopharmacology(Berl), 235, pp.2859~2869 (2018)
  18. Li H, "Efficacy and safety of quetiapine extended release monotherapy in bipolar depression:a multi-center, randomized, double-blind, placebo-controlled trial", Psychopharmacology(Berl), 233, pp.1289~1297 (2016)
  19. Bartoli F, "Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression : a meta-analysis", J Psychiatr Res, 88, pp.38~46 (2017)
  20. Geddes JR, "Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy(and folic acid versus placebo)in bipolar depression(CEQUEL) : a 2 x 2 factorial randomised trial", Lancet Psychiatry, 3, pp.31~39 (2016)
  21. Maneeton B, "Quetiapine monotherapy versus placebo in the treatment of children and adolescents with bipolar depression : a systematic review and meta-analysis", Neuropsychiatr Dis Treat, 13, pp.1023~1032 (2017)
  22. 서정석, "한국형 양극성 장애 약물치료 알고리듬 2018 : 우울 삽화", Mood and Emotion, 16(2), pp.57~68 (2018), 대한우울조울병학회
  23. Tohen M, "Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression", Arch Gen Psychiatry, 60, pp.1079~1088 (2003)
  24. Tohen M, "Randomised, double-blind, placebo-controlled study of olanzapine in patients with bipolar I depression", Br J Psychiatry, 201, pp.376~382 (2012)
  25. Amsterdam JD, "Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction", J Affect Disord, 87, pp.121~130 (2005)
  26. Wang G, "Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Chinese subpopulation analysis of a double-blind, randomized, placebo-controlled study", Neuropsychiatr Dis Treat, 12, pp.2077~2087 (2016)
  27. Wang M, "Efficacy of olanzapine monotherapy for treatment of bipolar I depression: a randomized, double-blind, placebo controlled study", Psychopharmacology(Berl), 231, pp.2811~2818 (2014)
  28. Katagiri H, "Efficacy and safety of olanzapine for treatment of patients with bipolar depression: Japanese subpopulation analysis of a randomized, double-blind, placebo-controlled study", BMC Psychiatry, 13, pp.138~ (2013)
  29. Corya SA, "A 24-week open-label extension study of olanzapine-fluoxetine combination and olanzapine monotherapy in the treatment of bipolar depression", J Clin Psychiatry, 67, pp.798~806 (2006)
  30. Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP)treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3: the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
  31. Findlay LJ, "Management of bipolar I depression : clinical utility of lurasidone", Ther Clin Risk Manag, 11, pp.75~81 (2015)
  32. Loebel A, "Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebocontrolled study", Am J Psychiatry, 171, pp.169~177 (2014)
  33. Ostacher M, "Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: a systematic review and network meta-analysis", World J Biol Psychiatry (2017)
  34. Suppes T, "Lurasidone adjunctive with lithium or valproate for bipolar depression : a placebo-controlled trial utilizing prospective and retrospective enrolment cohorts", J Psychiatr Res, 78, pp.86~93 (2016)
  35. DelBello MP, "Efficacy and safety of lurasidone in children and adolescents with bipolar I depression: a double-blind, placebo-controlled study", J Am Acad Child Adolesc Psychiatry, 56, pp.1015~1025 (2017)
  36. Ketter TA, "Balancing benefits and harms of treatments for acute bipolar depression", J Affect Disord, 169(Suppl 1), pp.S24~S33 (2014)
  37. Di Sciascio G, "Aripiprazole : from pharmacological profile to clinical use", Neuropsychiatr Dis Treat, 11, pp.2635~2647 (2015)
  38. Thase ME, "Aripiprazole monotherapy in nonpsychotic bipolar I depression:results of 2 randomized, placebo-controlled studies", J Clin Psychopharmacol, 28, pp.13~20 (2008)
  39. Dunn RT, "A prospective, open-label study of Aripiprazole mono- and adjunctive treatment in acute bipolar depression", J Affect Disord, 110, pp.70~74 (2008)
  40. Kelly T, "The utility of low-dose aripiprazole for the treatment of bipolar II and bipolar NOS depression", J Clin Psychopharmacol, 37, pp.99~101 (2017)
  41. Veselinović T, "Cariprazine, a new, orally active dopamine D2", 3 receptor partial agonist for the treatment of schizophrenia, bipolar mania and depression, 2013, pp.13, 1141~1159
  42. Durgam S, "An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression", Am J Psychiatry, 173, pp.271~281 (2016)
  43. "Allergan.com" (2018)[URL]
  44. Keck PE Jr, "Ziprasidone : a new atypical antipsychotic", Expert Opin Pharmacother, 2, pp.1033~1042 (2001)
  45. Lombardo I, "Two 6-week, randomized, double-blind, placebo-controlled studies of ziprasidone in outpatients with bipolar I depression: did baseline characteristics impact trial outcome?", J Clin Psychopharmacol, 32, pp.470~478 (2012)
  46. Sachs GS, "Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial", J Clin Psychiatry, 72, pp.1413~1422 (2011)
  47. Liebowitz MR, "Ziprasidone monotherapy in bipolar II depression : an open trial", J Affect Disord, 118, pp.205~208 (2009)
  48. Shelton RC, "Risperidone and paroxetine given singly and in combination for bipolar depression", J Clin Psychiatry, 65, pp.1715~1719 (2004)
  49. Geddes JR, "Lamotrigine for treatment of bipolar depression : independent meta-analysis and meta-regression of individual patient data from five randomised trials", Br J Psychiatry, 194, pp.4~9 (2009)
  50. Calabrese JR, "A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 study group", J Clin Psychiatry, 60, pp.79~88 (1999)
  51. van der Loos ML, "Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial", J Clin Psychiatry, 70, pp.223~231 (2009)
  52. Ahn YM, "Lamotrigine plus quetiapine combination therapy in treatment-resistant bipolar depression", Ann Clin Psychiatry, 23, pp.17~24 (2011)
  53. "Fda.gov" (2018)[URL]
  54. Ignaszewski M, "Lamotrigine-associated hemophagocytic lymphohistiocytosis", Am J Ther, 24, pp.e493~ (2017)
  55. Nemeroff CB, "Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression", Am J Psychiatry, 158, pp.906~912 (2001)
  56. Machado-Vieira R, "Lithium efficacy in bipolar depression with flexible dosing: a six-week, open-label, proof-of-concept study", Exp Ther Med, 8, pp.1205~1208 (2014)
  57. Toffol E, "Lithium is associated with decrease in all-cause and suicide mortality in high-risk bipolar patients : a nationwide registry-based prospective cohort study", J Affect Disord, 183, pp.159~165 (2015)
  58. Fieve RR, "Lithium prophylaxis of depression in bipolar I, bipolar II, and unipolar patients", Am J Psychiatry, 133, pp.925~929 (1976)
  59. Davis LL, "Divalproex in the treatment of bipolar depression : a placebo-controlled study", J Affect Disord, 85, pp.259~266 (2005)
  60. Ghaemi SN, "Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study", J Clin Psychiatry, 68, pp.1840~1844 (2007)
  61. Bond DJ, "Divalproex sodium versus placebo in the treatment of acute bipolar depression : a systematic review and meta-analysis", J Affect Disord, 124, pp.228~234 (2010)
  62. Wang PW, "Divalproex extended-release in acute bipolar II depression", J Affect Disord, 124, pp.170~173 (2010)
  63. Winsberg ME, "Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression", J Affect Disord, 67, pp.207~212 (2001)
  64. Gyulai L, "Maintenance efficacy of divalproex in the prevention of bipolar depression", Neuropsychopharmacology, 28, pp.1374~1382 (2003)
  65. Sachs GS, "Effectiveness of adjunctive antidepressant treatment for bipolar depression", N Engl J Med, 356, pp.1711~1722 (2007)
  66. Sidor MM, "Antidepressants for the acute treatment of bipolar depression : a systematic review and meta-analysis", J Clin Psychiatry, 72, pp.156~167 (2011)
  67. McGirr A, "Safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute bipolar depression : a systematic review and meta-analysis of randomised placebo-controlled trials", Lancet Psychiatry, 3, pp.1138~1146 (2016)
  68. Viktorin A, "The risk of switch to mania in patients with bipolar disorder during treatment with an antidepressant alone and in combination with a mood stabilizer", Am J Psychiatry, 171, pp.1067~1073 (2014)
  69. Tondo L, "Mania associated with antidepressant treatment : comprehensive meta-analytic review", Acta Psychiatr Scand, 121, pp.404~414 (2010)
  70. Pacchiarotti I, "The International Society for Bipolar Disorders(ISBD)task force report on antidepressant use in bipolar disorders", Am J Psychiatry, 170, pp.1249~1262 (2013)
  71. Frye MA, "A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar depression", Am J Psychiatry, 164, pp.1242~1249 (2007)
  72. Goss AJ, "Modafinil augmentation therapy in unipolar and bipolar depression : a systematic review and meta-analysis of randomized controlled trials", J Clin Psychiatry, 74, pp.1101~1107 (2013)
  73. Calabrese JR, "Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder: a randomized, multicenter, double-blind, placebocontrolled, proof-of-concept study", J Clin Psychiatry, 71, pp.1363~1370 (2010)
  74. Calabrese JR, "Efficacy and safety of adjunctive armodafinil in adults with major depressive episodes associated with bipolar I disorder: a randomized, double-blind, placebo-controlled, multicenter trial", J Clin Psychiatry, 75, pp.1054~1061 (2014)
  75. Ketter TA, "Adjunctive armodafinil for major depressive episodes associated with bipolar I disorder", J Affect Disord, 181, pp.87~91 (2015)
  76. Frye MA, "Randomized, placebo-controlled, adjunctive study of armodafinil for bipolar I depression: implications of novel drug design and heterogeneity of concurrent bipolar maintenance treatments", Int J Bipolar Disord, 3, pp.34~ (2015)
  77. Ketter TA, "Long-term safety and efficacy of armodafinil in bipolar depression : a 6-month open-label extension study", J Affect Disord, 197, pp.51~57 (2016)
  78. Goldberg JF, "Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression", Am J Psychiatry, 161, pp.564~566 (2004)
  79. Zarate CA Jr, "Pramipexole for bipolar II depression : a placebocontrolled proof of concept study", Biol Psychiatry, 56, pp.54~60 (2004)
  80. Dell’Osso B, "Assessing efficacy", effectiveness and safety, Int Clin Psychopharmacol, pp.2013, 28[DOI]
  81. Fawcett J, "Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression", Am J Psychiatry, 173, pp.107~111 (2016)
  82. Berk M, "N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial", Biol Psychiatry, 64, pp.468~475 (2008)
  83. Stamm TJ, "Supraphysiologic doses of levothyroxine as adjunctive therapy in bipolar depression: a randomized, double-blind, placebo-controlled study", J Clin Psychiatry, 75, pp.162~168 (2014)
  84. Zeinoddini A, "Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial", Depress Anxiety, 32, pp.167~173 (2015)
  85. Kemp DE, "PPAR-γ agonism as a modulator of mood : proof-of-concept for pioglitazone in bipolar depression", CNS Drugs, 28, pp.571~581 (2014)
  86. Sarris J, "Omega-3 for bipolar disorder : meta-analyses of use in mania and bipolar depression", J Clin Psychiatry, 73, pp.81~86 (2012)
  87. Keck PE Jr, "Double-blind, randomized, placebo-controlled trials of ethyleicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder", Biol Psychiatry, 60, pp.1020~1022 (2006)
  88. Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
  89. Morsel AM, "An overview of pharmacotherapy for bipolar I disorder", Expert Opin Pharmacother, 19, pp.203~222 (2018)

관련 논문AI추천

한국형 양극성 장애 약물치료 알고리듬 2022: 우울 삽화김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제2호Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines이정구, 전덕인, Bo-Hyun Yoon, Hoo-Rim Song, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2019 · 제17권 제2호Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines김문두, 박원명, 심세훈, 전덕인, 정종현, 추일한, Bo-Hyun Yoon, Chan-Mo Yang, Inki Sohn, Jeong Seok Seo, Jung Goo Lee, Myung Hun Jung, Sung-Yong Park, Won Kim, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2023 · 제21권 제1호한국형 양극성 장애 약물치료 알고리듬 2022: 급속 순환형김원, 김문두, 박성용, 박원명, 서정석, 손인기, 심세훈, 양찬모, 우영섭, 윤보현, 이정구, 전덕인, 정명훈, 정종현, 추일한대한신경정신의학회 · 신경정신의학2022 · 제61권 제3호Pharmacotherapy of Acute Bipolar Depression in Adults: An Evidence Based ApproachAther Muneer대한가정의학회 · Korean Journal of Family Medicine2016 · 제37권 제3호Korean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision송후림, Bo-Hyun Yoon, Duk-In Jon, Inki Sohn, Jeong Seok Seo, Jong Hyun Jeong, Jung Goo Lee, Kyung Joon Min, Moon Doo Kim, Se-Hoon Shim, Won Kim, Won-Myong Bahk, Young Sup Woo대한정신약물학회 · Clinical Psychopharmacology and Neuroscience2018 · 제16권 제4호

이 간행물의 다른 논문 (7건)

양극성장애의 퍼즐 풀기이헌정pp. 275-275일주기리듬의 조절이상이 양극성장애의핵심 발병 기전일까?이헌정pp. 276-286양극성장애에서 Antipsychotics의 사용 전략전홍진pp. 301-307양극성장애와 성격장애의 경계하태현pp. 308-316정신과 의사-환자 간의 성적인 경계위반장형윤, 임기영pp. 317-322
원문 보기